Cipro Inhaler for Cystic Fibrosis Children Ages 6-12

NCT ID: NCT00910351

Last Updated: 2013-11-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 19 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-07-31
• Study Completion Date: 2010-10-31

Brief Summary

Ciprofloxacin PulmoSphere Inhalation Powder appears to be an effective and adequate antibiotic treatment for cystic fibrosis patients with P. aeruginosa colonisation. This planned study is the first study on the use of this new Ciprofloxacin PulmoSphere Inhalation Powder in the pediatric population of 6 to 12 years of age.

Conditions

Pseudomonas Infection

Keywords

Cystic Fibrosis; Pharmacokinetics; Pediatrics; Inhalation; Sputum

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm 1

Group Type: EXPERIMENTAL

Ciprofloxacin (Cipro, BAYQ3939)

Intervention Type: DRUG

25 mg inhaled Ciprofloxacin

Interventions

Ciprofloxacin (Cipro, BAYQ3939)

25 mg inhaled Ciprofloxacin

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Male or female patients with cystic fibrosis confirmed by genetic testing and / or by sweat test
• Colonization with P. aeruginosa confirmed in sputum in the past 12 months
• Cohort 1: greater than or equal to 18 years of age.
• Cohort 2: 6 - 12 years of age (inclusive)
• Normal Body Mass Index: BMI between 14.5 and 30 kg/m2, but in no case lower than the 30th percentile for age. Because CF patients are typically smaller than non-CF-patients, the normal body mass index will be based on standard CF foundation normal values for weight and sex.
• Patients who are able to understand and follow instructions and who are able to participate in the study for the entire period.
• Patients and legal representatives must have given their written informed consent to participate in the study after receiving adequate previous information and prior to any study specific procedures

Exclusion Criteria

• Patients with FEV1 < 35% of predicted. FEV1 (forced expiratory volume) is a measure of lung function. This exclusion will prohibit enrollment of patients with severely impaired lung function.
• Patients with Burkholderia cepacia colonization of their respiratory tract
• Patients with acute bronchopulmonary aspergillosis (ABPA)
• Patients on a lung transplant list
• Patients with acute pulmonary exacerbations
• Patients with severe liver cirrhosis
• Massive hemoptysis in the preceding 4 weeks
• A history of relevant diseases of vital organs, of the central nervous system, or other organs not related to the underlying disease
• Patients with a history of severe allergies, non-allergic drug reactions, or multiple drug allergies
• Patients with hypersensitivity to the investigational drug or to other quinolones and/ or to inactive constituents
• Patients with known intolerance to hypertonic saline or bronchodilators
• Concomitant inhalation therapy with antibiotics and / or concomitant systemic therapy with fluoroquinolones
• Women who are pregnant

• Minimum Eligible Age: 6 Years
• Maximum Eligible Age: 12 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Bayer

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Bayer Study Director

Role: STUDY_DIRECTOR

Bayer

Locations

Atlanta, Georgia, United States

Baltimore, Maryland, United States

Boston, Massachusetts, United States

Syracuse, New York, United States

Countries

United States

Other Identifiers

12759

Identifier Type: -

Identifier Source: org_study_id